Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Harbour BioMed and Fox Chase Cancer Center initiated discussions related to opening clinical trials at Fox Chase using Harbour BioMed’s candidate oncology agents. Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases. Harbour BioMed’s current portfolio includes four clinical-stage in-licensed compounds and a rapidly emerging set of therapeutics coming from its internal discovery efforts as well as co-discovery/development collaborations with academic institutions and biopharmaceutical companies.
About Our Agreement
Confidentiality Agreement - details are confidential and cannot be disclosed to the public.